Janux Therapeutics, Inc.
JANX
$16.12
$0.120.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | 2,177.90% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | 2,177.90% | -- |
| Cost of Revenue | -10.59% | 7.02% | 51.63% | 86.04% | 132.68% |
| Gross Profit | 40.21% | 7.88% | -51.63% | -35.51% | -477.64% |
| SG&A Expenses | 4.87% | 13.12% | 32.10% | -39.88% | 33.67% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -7.01% | 8.74% | 46.10% | 24.72% | 98.59% |
| Operating Income | 29.76% | 1.96% | -46.10% | 1.65% | -226.42% |
| Income Before Tax | 35.11% | -3.63% | -58.02% | 13.35% | -468.18% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 35.11% | -3.63% | -58.02% | 13.35% | -468.18% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 35.11% | -3.63% | -58.02% | 13.35% | -468.18% |
| EBIT | 29.76% | 1.96% | -46.10% | 1.65% | -226.42% |
| EBITDA | 29.95% | 1.84% | -47.08% | 1.65% | -234.76% |
| EPS Basic | 36.18% | -2.18% | -44.53% | 23.68% | -400.00% |
| Normalized Basic EPS | 36.16% | -2.19% | -44.53% | 23.68% | -399.71% |
| EPS Diluted | 36.18% | -2.18% | -44.53% | 23.68% | -400.00% |
| Normalized Diluted EPS | 36.16% | -2.19% | -44.53% | 23.68% | -399.71% |
| Average Basic Shares Outstanding | 1.67% | 1.41% | 9.35% | 13.54% | 13.68% |
| Average Diluted Shares Outstanding | 1.67% | 1.41% | 9.35% | 13.54% | 13.68% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |